ProThera Biologics
Biotechnology ResearchUnited States11-50 Employees
ProThera Biologics is a biotechnology company based out of 551 Warren Ave, East Providence, Rhode Island, United States.
Innovative Therapeutics ProThera Biologics specializes in developing plasma-derived Inter-alpha Inhibitor Proteins for the treatment of severe inflammatory diseases, presenting opportunities to collaborate on advanced biopharmaceutical solutions targeting acute inflammatory conditions.
Research Collaborations With significant federal funding and partnerships with academic institutions and Takeda Pharmaceutical, ProThera demonstrates a strong research foundation, indicating potential for joint R&D initiatives or licensing of innovative biotechnologies.
Funding Momentum Having secured over $12 million in federal grants and additional private investments, ProThera is positioned for growth, making it a promising partner for funding-focused collaborations or clinical development support.
Market Entry Potential Focused on addressing life-threatening inflammatory diseases with novel therapies, ProThera offers opportunities to develop complementary products or diagnostics that can enhance their point-of-care testing capabilities.
Scalable Business Model Operating with an agile team of 11 to 50 employees and a revenue range of 1M to 10M, ProThera appears to be in an expansion phase, open to partnerships that can accelerate product development, commercialization, or market penetration.
ProThera Biologics uses 8 technology products and services including WordPress, MySQL, Google Workspace, and more. Explore ProThera Biologics's tech stack below.
| ProThera Biologics Email Formats | Percentage |
| First.Last@protherabiologics.com | 33% |
| FLast@protherabiologics.com | 17% |
| First.Last@protherabiologics.com | 33% |
| FLast@protherabiologics.com | 17% |
Biotechnology ResearchUnited States11-50 Employees
ProThera Biologics is a biotechnology company based out of 551 Warren Ave, East Providence, Rhode Island, United States.
ProThera Biologics has raised a total of $9.6M of funding over 4 rounds. Their latest funding round was raised on Jan 10, 2018 in the amount of $2Mas a debt financing.
ProThera Biologics's revenue is estimated to be in the range of $1M$10M
ProThera Biologics has raised a total of $9.6M of funding over 4 rounds. Their latest funding round was raised on Jan 10, 2018 in the amount of $2Mas a debt financing.
ProThera Biologics's revenue is estimated to be in the range of $1M$10M